Matches in SemOpenAlex for { <https://semopenalex.org/work/W176068902> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W176068902 endingPage "25" @default.
- W176068902 startingPage "S5" @default.
- W176068902 abstract "Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) has emerged as a promising new chemotherapy drug for patients with refractory and progressive stage III and IV epithelial ovarian carcinoma. A semisynthetic analog of camptothecin, topotecan exerts its antitumor effects through inhibition of the nuclear enzyme topoisomerase I. Phase I trials found antitumor activity in many topotecan dosing schedules, one of which involved the administration of topotecan daily as a 30-minute infusion for 5 consecutive days, with the cycle repeated every 21 days. With this schedule, the maximum tolerated dose was found to be 1.5 mg/m2/d. In a series of phase II investigations in platinum-resistant ovarian cancer patients, response rates have ranged from 13% to 25%. In addition, a number of patients exhibit prolonged disease stabilization, with overall rates of nonprogression ranging from 37% to 81%. Activity in paclitaxel-resistant patients is also seen, with a multicenter phase II trial showing a response rate of 13% among first-line paclitaxel failures and 14.3% among second-line failures. A phase III trial compared topotecan and paclitaxel as second-line therapies in 226 advanced ovarian cancer patients who had been previously treated with platinum-containing regimens. Preliminary data show that patients treated with topotecan evidenced a higher response rate (23% v 14%), longer response duration (32 weeks v 20 weeks), and significantly longer time to progression (23 weeks v 14 weeks; P = .002). Additional schedules are still being evaluated, with a phase II trial of prolonged infusion of relatively low-dose topotecan over 21 days demonstrating a 37% response rate in 16 patients. All phase II and III trials analyzed thus far indicate that topotecan is well tolerated with an acceptable toxicity profile, with myelosuppression as the dose-limiting toxicity. Hematologic toxicities are predictable, of short duration, and noncumulative. Mild to moderate nonhematologic toxicities are manageable. These findings demonstrate that topotecan is a viable new second-line or salvage treatment for patients with advanced ovarian cancer who are refractory or resistant to prior chemotherapy, including platinum-based agents and/or paclitaxel." @default.
- W176068902 created "2016-06-24" @default.
- W176068902 creator A5034539392 @default.
- W176068902 creator A5042639668 @default.
- W176068902 creator A5050062751 @default.
- W176068902 creator A5052430473 @default.
- W176068902 creator A5086136263 @default.
- W176068902 date "1997-02-01" @default.
- W176068902 modified "2023-10-16" @default.
- W176068902 title "Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma." @default.
- W176068902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9122738" @default.
- W176068902 hasPublicationYear "1997" @default.
- W176068902 type Work @default.
- W176068902 sameAs 176068902 @default.
- W176068902 citedByCount "9" @default.
- W176068902 crossrefType "journal-article" @default.
- W176068902 hasAuthorship W176068902A5034539392 @default.
- W176068902 hasAuthorship W176068902A5042639668 @default.
- W176068902 hasAuthorship W176068902A5050062751 @default.
- W176068902 hasAuthorship W176068902A5052430473 @default.
- W176068902 hasAuthorship W176068902A5086136263 @default.
- W176068902 hasConcept C121332964 @default.
- W176068902 hasConcept C121608353 @default.
- W176068902 hasConcept C126322002 @default.
- W176068902 hasConcept C141071460 @default.
- W176068902 hasConcept C142424586 @default.
- W176068902 hasConcept C143998085 @default.
- W176068902 hasConcept C147897179 @default.
- W176068902 hasConcept C178790620 @default.
- W176068902 hasConcept C185592680 @default.
- W176068902 hasConcept C202751555 @default.
- W176068902 hasConcept C2776694085 @default.
- W176068902 hasConcept C2777288759 @default.
- W176068902 hasConcept C2777292972 @default.
- W176068902 hasConcept C2779682216 @default.
- W176068902 hasConcept C2780427987 @default.
- W176068902 hasConcept C2781209748 @default.
- W176068902 hasConcept C3019054536 @default.
- W176068902 hasConcept C31760486 @default.
- W176068902 hasConcept C55493867 @default.
- W176068902 hasConcept C71924100 @default.
- W176068902 hasConcept C87355193 @default.
- W176068902 hasConcept C90924648 @default.
- W176068902 hasConcept C98274493 @default.
- W176068902 hasConceptScore W176068902C121332964 @default.
- W176068902 hasConceptScore W176068902C121608353 @default.
- W176068902 hasConceptScore W176068902C126322002 @default.
- W176068902 hasConceptScore W176068902C141071460 @default.
- W176068902 hasConceptScore W176068902C142424586 @default.
- W176068902 hasConceptScore W176068902C143998085 @default.
- W176068902 hasConceptScore W176068902C147897179 @default.
- W176068902 hasConceptScore W176068902C178790620 @default.
- W176068902 hasConceptScore W176068902C185592680 @default.
- W176068902 hasConceptScore W176068902C202751555 @default.
- W176068902 hasConceptScore W176068902C2776694085 @default.
- W176068902 hasConceptScore W176068902C2777288759 @default.
- W176068902 hasConceptScore W176068902C2777292972 @default.
- W176068902 hasConceptScore W176068902C2779682216 @default.
- W176068902 hasConceptScore W176068902C2780427987 @default.
- W176068902 hasConceptScore W176068902C2781209748 @default.
- W176068902 hasConceptScore W176068902C3019054536 @default.
- W176068902 hasConceptScore W176068902C31760486 @default.
- W176068902 hasConceptScore W176068902C55493867 @default.
- W176068902 hasConceptScore W176068902C71924100 @default.
- W176068902 hasConceptScore W176068902C87355193 @default.
- W176068902 hasConceptScore W176068902C90924648 @default.
- W176068902 hasConceptScore W176068902C98274493 @default.
- W176068902 hasIssue "1 Suppl 5" @default.
- W176068902 hasLocation W1760689021 @default.
- W176068902 hasOpenAccess W176068902 @default.
- W176068902 hasPrimaryLocation W1760689021 @default.
- W176068902 hasRelatedWork W176068902 @default.
- W176068902 hasRelatedWork W1978427220 @default.
- W176068902 hasRelatedWork W1992396964 @default.
- W176068902 hasRelatedWork W2016731430 @default.
- W176068902 hasRelatedWork W2253817994 @default.
- W176068902 hasRelatedWork W2298378430 @default.
- W176068902 hasRelatedWork W2461409983 @default.
- W176068902 hasRelatedWork W2466209479 @default.
- W176068902 hasRelatedWork W36592736 @default.
- W176068902 hasRelatedWork W4233029719 @default.
- W176068902 hasVolume "24" @default.
- W176068902 isParatext "false" @default.
- W176068902 isRetracted "false" @default.
- W176068902 magId "176068902" @default.
- W176068902 workType "article" @default.